^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Intron A (interferon α-2b)

    i
    Other names: SCH 30500, YM 14090
    Company:
    Biogen, Merck (MSD)
    Drug class:
    IFNα 2b stimulant
    Related drugs:
    4d
    Study on the Impact and Safety of Vaginal Lactobacillus Viable Capsules on the Clearance Rate of High‑Risk HPV Infection in Postmenopausal Women (ChiCTR2500114563)
    P4, N=222, Not yet recruiting, Women’s Hospital, Zhejiang University School of Medicine; Women’s Hospital, Zhejiang University School of Medicine
    New P4 trial
    |
    Intron A (interferon α-2b)
    21d
    Rintatolimod and IFN Alpha-2b for the Treatment of COVID-19 in Cancer Patients (clinicaltrials.gov)
    P1/2, N=4, Terminated, Roswell Park Cancer Institute | N=64 --> 4 | Suspended --> Terminated; Low accrual
    Enrollment change • Trial termination
    |
    CCL22 (C-C Motif Chemokine Ligand 22)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod)
    27d
    Phase II trial of interleukin-12 followed by interferon alfa-2b in patients with metastatic malignant melanoma: Results from CALGB 500001 (Alliance). (PubMed, Cancer Immunol Res)
    Combination therapy was reasonably well-tolerated but conferred marginal benefit in patients with metastatic melanoma. These results can inform future studies that employ recombinant IL-12 or novel IL-12 constructs.
    P2 data • Journal
    |
    IFNG (Interferon, gamma) • STAT1 (Signal Transducer And Activator Of Transcription 1) • IFNA1 (Interferon Alpha 1) • STAT2 (Signal transducer and activator of transcription 2)
    |
    Intron A (interferon α-2b)
    5ms
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=30 --> 12 | Trial primary completion date: Nov 2026 --> Jun 2025
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    7ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=1, Terminated, Roswell Park Cancer Institute | Trial completion date: Apr 2026 --> Jun 2025 | Active, not recruiting --> Terminated; Funding completed
    Trial completion date • Trial termination
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    9ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=1, Active, not recruiting, Roswell Park Cancer Institute | Recruiting --> Active, not recruiting | N=24 --> 1 | Trial completion date: Nov 2027 --> Apr 2026 | Trial primary completion date: Nov 2027 --> Apr 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    10ms
    NCI-2019-01192: Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery (clinicaltrials.gov)
    P2, N=30, Recruiting, Roswell Park Cancer Institute | Suspended --> Recruiting | Trial completion date: May 2026 --> Nov 2026 | Trial primary completion date: May 2026 --> Nov 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aspirin
    10ms
    E1609: Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1673, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2025 --> Mar 2026
    Trial completion date
    |
    IFNA1 (Interferon Alpha 1)
    |
    Yervoy (ipilimumab) • Intron A (interferon α-2b)
    11ms
    SWOG S1404: Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery (clinicaltrials.gov)
    P3, N=1301, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026
    Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Intron A (interferon α-2b)
    11ms
    Hypoxia-induced ATF3 escalates breast cancer invasion by increasing collagen deposition via P4HA1. (PubMed, Cell Death Dis)
    These results reveal a novel hypoxia-induced HIF1ɑ-ATF3-P4HA1 axis which can potentially be exploited as a therapeutic target to impede EMT and ultimately breast cancer invasion. Hypoxia induced ATF3 regulates P4HA1 expression and alternative splicing to promote breast cancer invasion.
    Journal
    |
    HIF1A (Hypoxia inducible factor 1, alpha subunit) • ATF3 (Activating Transcription Factor 3) • P4HA1 (Prolyl 4-Hydroxylase Subunit Alpha 1)
    |
    Intron A (interferon α-2b)
    11ms
    Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (clinicaltrials.gov)
    P2, N=24, Recruiting, Roswell Park Cancer Institute | Trial completion date: Nov 2025 --> Nov 2027 | Trial primary completion date: Nov 2025 --> Nov 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    CD8 (cluster of differentiation 8)
    |
    Intron A (interferon α-2b) • Ampligen (rintatolimod) • aDC1 vaccine • celecoxib oral
    1year
    MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (clinicaltrials.gov)
    P3, N=586, Recruiting, University of Birmingham | Trial completion date: Feb 2028 --> Apr 2030 | Trial primary completion date: Aug 2026 --> Oct 2028
    Trial completion date • Trial primary completion date
    |
    Jakafi (ruxolitinib) • hydroxyurea • Intron A (interferon α-2b)